Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 77 Show results per page	View Search Criteria \| Help With Results


1.		Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				HFHS 05-03 NCT00448240

Last Modified: 5/18/2007 First Published: 7/1/2002


2.		Phase III Randomized Study of Ad5CMV-p53 Gene Therapy (INGN 201) Versus Methotrexate in Patients With Refractory Squamous Cell Carcinoma of the Head and Neck (T301)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				INTROGEN-T301 NCT00041613

Last Modified: 5/27/2008 First Published: 7/1/2002


3.		Phase III Randomized Study of Cisplatin and Fluorouracil With Versus Without Ad5CMV-p53 Gene Therapy (INGN 201) in Patients With Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (T302)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				INTROGEN-T302 UCLA-0312111-01, NCT00041626


4.		Study Of Zd1839 (Iressa™) Versus Methotrexate For Previously Treated Patients With Squamous Cell Carcinoma Of The Head And Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				ZD1839IL/0704 NCT00072878

Last Modified: 10/22/2008 First Published: 7/23/2004


5.		Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1302 E1302, NCT00088907


6.		A Study for Patients With Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				8431 H3E-MC-JMHR, NCT00415194


7.		SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				20050251 SPECTRUM, 20050251, NCT00460265

Last Modified: 10/22/2008 First Published: 12/27/2007


8.		Phase III Randomized Study of Cisplatin-Containing Chemotherapy With Versus Without Bevacizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1305 E1305, NCT00588770


9.		Nutrition and Resistance Training in Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				21 and over				Other				080219 NCT00696553


10.		Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				0120070101 NCT00705068

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute